SIR-T CLDN-18.2

SIR-T CLDN-18.2 is an engineered cell therapy candidate developed by Angeles Therapeutics, currently in late preclinical development. The therapy utilizes the company's proprietary Synthetic Intracellular Receptor (SIR-T) platform, which is designed to engineer T cells with enhanced signaling capabilities to overcome the immunosuppressive tumor microenvironment. Specifically, this asset targets Claudin-18.2 (CLDN-18.2), a tight junction protein that is highly expressed in several solid tumors, including gastric, esophageal, and pancreatic cancers, while remaining largely absent in healthy tissues. The SIR-T architecture aims to improve the potency, activation, and durability of the T-cell response against these CLDN-18.2-positive malignancies.